Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press810.17650/2222-8721-2014-0-1-21-29LECTURES AND REVIEWSЛЕКЦИИ И ОБЗОРЫMalignant hyperthermia (icarus syndrome): new view on the old problemЗлокачественная гипертермия (синдром Икара): новый взгляд на старую проблемуShnayderN. A.ШнайдерН. А.
Russian Federation
NASchnaider@yandex.ruShnayderV. A.ШнайдерВ. А.
Russian Federation
Prof. V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Postgraduate Education Institute, Department of Medical Genetics and Clinical NeurophysiologyКафедра медицинской генетики и клинической нейрофизиологии Института последипломного образования ГБОУ ВПО «Красноярский государственный университет им. проф. В.Ф. Войно-Ясенецкого»Krasnoyarsk Regional Hospital, Division of Anaesthesiology and Rheanimatologyотделение анестезиологии и реанимации КГБУЗ «Красноярская краевая клиническая больница»190420144121291802201518022015Copyright ©; 2014, Shnayder N.A., Shnayder V.A.Copyright ©; 2014, Шнайдер Н.А., Шнайдер В.А.2014Shnayder N.A., Shnayder V.A.Шнайдер Н.А., Шнайдер В.А.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/8

In the lecture shot history of research of etiology and pathogenesis of more dramatic complication of general anaesthesia – malignant hyperthermia - are presented. Importance of the interdisciplinary approach to working out of methods of preventive maintenance and treatment of it pharmacogenetics conditions in practice of the anaesthesiologist is underlined.

В лекции освещена краткая история изучения вопросов этиологии и патогенеза одного из наиболее драматических осложнений общей анестезии – злокачественной гипертермии (синдрома Икара). Подчеркнута важность междисциплинарного подхода к разработке методов профилактики и лечения этого фармакогенетического состояния в практике невролога и анестезиолога.

malignant hyperthermiahistorygeneticsneuromuscular disordersanaesthesiology.злокачественная гипертермияисториягенетиканейромышечные болезнианестезиология1. Шнайдер Н.А. Злокачественная гипертермия: генетика, диагностика, профилактика. Острые и неотложные состояния в практике врача 2007;4:32–6.Шнайдер Н.А. Злокачественная гипертермия: генетика, диагностика, профилактика. Острые и неотложные состояния в практике врача 2007;4:32–6.2. Гринштейн А.Б., Шнайдер Н.А., Шнайдер В.А. Неврологические осложнения общей анестезии — особенности клиники, диагностики и лечения. Метод. рекомендации. Красноярск: КрасГМА, 2000.Гринштейн А.Б., Шнайдер Н.А., Шнайдер В.А. Неврологические осложнения общей анестезии — особенности клиники, диагностики и лечения. Метод. рекомендации. Красноярск: КрасГМА, 2000.3. Baker K.R., Landriscina D., Kartchner H., Mirkes D.M. The Icarus effect: the influenceof diluent warming on dantrolene sodium mixing time. AANA J 2007;75(2):101–6.Baker K.R., Landriscina D., Kartchner H., Mirkes D.M. The Icarus effect: the influenceof diluent warming on dantrolene sodium mixing time. AANA J 2007;75(2):101–6.4. Brandom B.W. The genetics of malignant hyperthermia. Anesthesiol Clin North America 2005;23(4):615–9.Brandom B.W. The genetics of malignant hyperthermia. Anesthesiol Clin North America 2005;23(4):615–9.5. Dinman S. Malignant hyperthermia. Plast Surg Nurs 2006;26(4):206–7.Dinman S. Malignant hyperthermia. Plast Surg Nurs 2006;26(4):206–7.6. Rosenberg H., Davis M., James D. et al. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.Rosenberg H., Davis M., James D. et al. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.7. Denborough M.A., Forster J.F., Lovell R.R. et al. Anaesthetic deaths in a family. British J Anaesth 1962;34:395–6.Denborough M.A., Forster J.F., Lovell R.R. et al. Anaesthetic deaths in a family. British J Anaesth 1962;34:395–6.8. Glahn K.P. Malignant hyperthermia. Ugeskr Laeger 2003;165(17):1763–8.Glahn K.P. Malignant hyperthermia. Ugeskr Laeger 2003;165(17):1763–8.9. Шнайдер Н.А., Салмина А.Б. Неврологические осложнения общей анестезии (2-е изд., перераб. и доп.). М.: Медика, 2009. 280 с.Шнайдер Н.А., Салмина А.Б. Неврологические осложнения общей анестезии (2-е изд., перераб. и доп.). М.: Медика, 2009. 280 с.10. Larach M.G., Gronert G.A., Allen G.C. et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010;110(2):498–507.Larach M.G., Gronert G.A., Allen G.C. et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010;110(2):498–507.11. Harrison G.G., Biebuyck J.F., Terblanche J. et al. Hyperpyrexia during anaesthesia. Br Med J 1968;3(5618):594–5.Harrison G.G., Biebuyck J.F., Terblanche J. et al. Hyperpyrexia during anaesthesia. Br Med J 1968;3(5618):594–5.12. Ohnishi S.T., Katsuoka M. Why does halothane relax cardiac muscle but contract malignant hyperthermic skeletal muscle? Adv Exp Med Biol 1991;301:73–87.Ohnishi S.T., Katsuoka M. Why does halothane relax cardiac muscle but contract malignant hyperthermic skeletal muscle? Adv Exp Med Biol 1991;301:73–87.13. Huxley H.E. The mechanism of muscular contraction. Science 1969;164(3886):1356–65.Huxley H.E. The mechanism of muscular contraction. Science 1969;164(3886):1356–65.14. Britt B.A., Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970;17(4):293–315.Britt B.A., Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970;17(4):293–315.15. Ellis F.R., Harriman D.G., Keaney N.P. et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971;43(7):721–2.Ellis F.R., Harriman D.G., Keaney N.P. et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971;43(7):721–2.16. Karan S.M., Lojeski E.W., Haynes D.H. et al. Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. Anesth Analg 1996;82(4):796–802.Karan S.M., Lojeski E.W., Haynes D.H. et al. Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. Anesth Analg 1996;82(4):796–802.17. MacLennan D.H., Phillips M.S. Malignant hyperthermia. Sci 1992;256:789–94.MacLennan D.H., Phillips M.S. Malignant hyperthermia. Sci 1992;256:789–94.18. Meola G., Sansone V., Rotondo G. et al. Muscle biopsy and cell cultures: potential diagnos-tic tools in hereditary skeletal muscle channelopathies. Eur J Histochem 2003;47(1):17–28.Meola G., Sansone V., Rotondo G. et al. Muscle biopsy and cell cultures: potential diagnos-tic tools in hereditary skeletal muscle channelopathies. Eur J Histochem 2003;47(1):17–28.19. Ellis K.O., Castellion A.W., Honkomp L.J. et al. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci 1973;62(6):948–51.Ellis K.O., Castellion A.W., Honkomp L.J. et al. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci 1973;62(6):948–51.20. Harrison G.G. Death attributable to anaesthesia. A 10-year survey (1967–1976). Br J Anaesth 1978;50(10):1041–6.Harrison G.G. Death attributable to anaesthesia. A 10-year survey (1967–1976). Br J Anaesth 1978;50(10):1041–6.21. Gronert G.A., Milde J.H., Theye R.A. Dantrolene in porcine malignant hyperthermia. Anesthesiology 1976;44(6):488–95.Gronert G.A., Milde J.H., Theye R.A. Dantrolene in porcine malignant hyperthermia. Anesthesiology 1976;44(6):488–95.22. Kolb M.E., Horne M.L., Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56(4):254–62.Kolb M.E., Horne M.L., Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56(4):254–62.23. Picard J., Ward S., Meek T. Antidotes to anesthetic catastrophe: lipid emulsion and dantrolene. Anesth Analg 2007;105(1):283–4.Picard J., Ward S., Meek T. Antidotes to anesthetic catastrophe: lipid emulsion and dantrolene. Anesth Analg 2007;105(1):283–4.24. Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine recep-tor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276(17):13810–6.Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine recep-tor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276(17):13810–6.25. Шнайдер Н.А. Злокачественная гипертермия: лечение. Острые и неотложные состояния в практике врача 2007;5:30–3.Шнайдер Н.А. Злокачественная гипертермия: лечение. Острые и неотложные состояния в практике врача 2007;5:30–3.26. Rosenberg H., Antognini J..F., Muldoon S. Testing for malignant hyperthermia. Anesth 2002;96:232–7.Rosenberg H., Antognini J..F., Muldoon S. Testing for malignant hyperthermia. Anesth 2002;96:232–7.27. Ta T.A., Pessah I.N. Ryanodine receptor type 1 (RYR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by noncoplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95). Neurotoxicology 2007;28(4):770–9.Ta T.A., Pessah I.N. Ryanodine receptor type 1 (RYR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by noncoplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95). Neurotoxicology 2007;28(4):770–9.28. Lanner J.T. Ryanodine receptor physiology and its role in disease. Adv Exp Med Biol 2012;740:217–4.Lanner J.T. Ryanodine receptor physiology and its role in disease. Adv Exp Med Biol 2012;740:217–4.29. Hubner C.A., Jentsch T.J. Ion channel diseases. Hum Mol Gen 2002;11(20):2435–45.Hubner C.A., Jentsch T.J. Ion channel diseases. Hum Mol Gen 2002;11(20):2435–45.30. Hudson A.J., Ebers G.C., Bulman D.E. The skeletal muscle sodium and chloride channel diseases. Brain 1995;118:547–63.Hudson A.J., Ebers G.C., Bulman D.E. The skeletal muscle sodium and chloride channel diseases. Brain 1995;118:547–63.31. MacLennan D.H., Duff C., Zorzato F. et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990;343(6258): 559–61.MacLennan D.H., Duff C., Zorzato F. et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990;343(6258): 559–61.32. McCarthy T.V., Datar S., Mackrill J.J. Activation of ryanodine receptor/Ca2+ release channels downregulates CD38 in the Namalwa B lymphoma. FEBS Lett 2003;554(1-2):133–7.McCarthy T.V., Datar S., Mackrill J.J. Activation of ryanodine receptor/Ca2+ release channels downregulates CD38 in the Namalwa B lymphoma. FEBS Lett 2003;554(1-2):133–7.33. MacLennan D.H., Chen S.R. Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes. J Physiol 2009;587(Pt 13):3113–5.MacLennan D.H., Chen S.R. Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes. J Physiol 2009;587(Pt 13):3113–5.34. Katsuya H., Misumi M., Ohtani Y., Miike T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiol 1988;68(6):945–8.Katsuya H., Misumi M., Ohtani Y., Miike T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiol 1988;68(6):945–8.35. Zierz S., Schmitt U. Inhibition of carnitine palmitoyltransferase by malonyl-CoA in human muscle is influenced by anesthesia. Anesthesiol 1989;70(2):373.Zierz S., Schmitt U. Inhibition of carnitine palmitoyltransferase by malonyl-CoA in human muscle is influenced by anesthesia. Anesthesiol 1989;70(2):373.36. Fiege M., Wappler F., Weisshorn R. et al. In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiol 2003;98(4):944–9.Fiege M., Wappler F., Weisshorn R. et al. In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiol 2003;98(4):944–9.37. Fruen B.R., Mickelson J.R., Louis C.F. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem 1997;272(43):26965–71.Fruen B.R., Mickelson J.R., Louis C.F. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem 1997;272(43):26965–71.38. Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276(17):13810–86.Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276(17):13810–86.39. Jurkat R.K., Lerche H., Mitrovic N. et al. Teaching course: ion channelopathies in neurology. J Neurol 1999;46:758–63.Jurkat R.K., Lerche H., Mitrovic N. et al. Teaching course: ion channelopathies in neurology. J Neurol 1999;46:758–63.40. Guis S., Figarella-Branger D., Monnier N. et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004;61:106–13.Guis S., Figarella-Branger D., Monnier N. et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004;61:106–13.41. Islander G., Jungner M. Anesthesia in hereditary peripheral muscular disease. Lakartidningen 2005;102(8):566–71.Islander G., Jungner M. Anesthesia in hereditary peripheral muscular disease. Lakartidningen 2005;102(8):566–71.42. Halsall P.J., Bridges L.R., Ellis F.R., Hopkins P.M. Should patients with central core disease be screened for malignant hyperthermia? J Neurol Neurosurg Psychiatry1996;61:119–21.Halsall P.J., Bridges L.R., Ellis F.R., Hopkins P.M. Should patients with central core disease be screened for malignant hyperthermia? J Neurol Neurosurg Psychiatry1996;61:119–21.43. Jensen V. The anaesthetic management of a patient with Emery-Dreifuss muscular dystrophy. Can J Anaesth 1996;43(9):968–71.Jensen V. The anaesthetic management of a patient with Emery-Dreifuss muscular dystrophy. Can J Anaesth 1996;43(9):968–71.44. Litman R.S., Rosenberg H. Malignant hyperthermia-associated diseases: State of the Art uncertainty. Anesth Analg 2009;109:1004–5.Litman R.S., Rosenberg H. Malignant hyperthermia-associated diseases: State of the Art uncertainty. Anesth Analg 2009;109:1004–5.45. Kim D.C. Malignant hyperthermia. Korean J Anesthesiol 2012;63(5):391–401.Kim D.C. Malignant hyperthermia. Korean J Anesthesiol 2012;63(5):391–401.46. Pollock N.A., Langton E.E. Management of malignant hyperthermia susceptible parturients. Anaesth Intensive Care 1997;25(4):398–407.Pollock N.A., Langton E.E. Management of malignant hyperthermia susceptible parturients. Anaesth Intensive Care 1997;25(4):398–407.47. Baker K.R., Landriscina D., Kartchner H., Mirkes D.M. The Icarus effect: the influence of diluent warming on dantrolene sodium mixing time. AANA J 2007;75(2):101–6.Baker K.R., Landriscina D., Kartchner H., Mirkes D.M. The Icarus effect: the influence of diluent warming on dantrolene sodium mixing time. AANA J 2007;75(2):101–6.48. Naguib M., Flood P., McArdle J.J., Brenner H.R. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 2002;(96):202–31.Naguib M., Flood P., McArdle J.J., Brenner H.R. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 2002;(96):202–31.49. Hirshey Dirksen S.J., Larach M.G., Rosenberg H. et al. Special article: Future directions in malignant hyperthermia research and patient care Anesth Analg 2011;113(5):1108–19.Hirshey Dirksen S.J., Larach M.G., Rosenberg H. et al. Special article: Future directions in malignant hyperthermia research and patient care Anesth Analg 2011;113(5):1108–19.50. Stowell K.M. Malignant hyperthermia: a pharmacogenetic disorder. Pharmacogenomics 2008;9:1657–72.Stowell K.M. Malignant hyperthermia: a pharmacogenetic disorder. Pharmacogenomics 2008;9:1657–72.